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Abstract
Background: Congenital factor VII (FVII) deficiency is a rare autosomal recessive coagulation disorder that is
characterized by prolongation of prothrombin time. Recombinant activated FVII (rFVIIa) is widely used in the
management of bleeding in patients with congenital FVII deficiency. We experienced anesthetic management
of a patient with congenital FVII deficiency who was scheduled for laparoscopic colectomy using rFVIIa.
Case presentation: We report a 67-year-old man with rectal cancer who was diagnosed with congenital FVII
deficiency. He was scheduled for laparoscopic colectomy. General anesthesia was performed with propofol,
remifentanil, and rocuronium without epidural anesthesia. For coagulation management, 1 mg of rFVIIa was
intravenously administered before starting surgery. During surgery, FVII activity and prothrombin time-international
normalized ratio (PT-INR) were maintained to be above 10 % and within the normal range (0.8–1.2), respectively.
The surgery was uneventfully completed.
Conclusions: We reported successful management of a patient with congenital FVII deficiency undergoing
laparoscopic colectomy with monitoring of FVII activity and/or PT-INR.
Keywords: Congenital FVII deficiency, Coagulation management, Recombinant activated FVII, Surgical bleeding
Background
Factor VII (FVII), which is a vitamin K-dependent
coagulation factor, plays a role in initiation of the extrin-
sic coagulation pathway with tissue factor. Its congenital
deficiency is a rare autosomal recessive coagulation
disorder with an estimated prevalence of about
1:500,000 [1]. FVII deficiency can be suspected when a
coagulation screening test reveals an isolated prolonga-
tion of prothrombin time (PT) with a normal activated
partial thromboplastin time (aPTT). Congenital FVII
deficiency is diagnosed when patients show a decrease in
only FVII among the coagulant factors without having
any liver disease, not taking any medication that inhibits
FVII activity, and not having an acquired inhibitor of
FVII. Patients with congenital deficiency of FVII have an
increased risk of postoperative bleeding [2]. Administra-
tion of recombinant activated FVII (rFVIIa) is widely
accepted as a therapeutic option for both spontaneous
bleeding and surgical bleeding in patients with congeni-
tal FVII deficiency. However, a treatment strategy for
surgical bleeding has not been established [3], and there
is only one report regarding anesthetic management of a
patient with factor VII deficiency [4]. Here, we report
anesthetic management of a patient with congenital
FVII deficiency who was scheduled for laparoscopic
colectomy. We intravenously administered rFVIIa and
monitored FVII activity and/or prothrombin time-
international normalized ratio (PT-INR) during the
perioperative period.
Case presentation
Written informed consent was obtained from the patient
for this case report.
A 67-year-old man (170 cm, 71 kg) was admitted to
our hospital to undergo laparoscopic colectomy for rec-
tal cancer. He had no significant past medical history
including bleeding disorder, and his family history was
also unremarkable. Preoperative laboratory tests showed
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an abnormal coagulation profile. Although his aPTT and
platelet count were normal (29.6 s and 23.1 × 104 μl,
respectively), his PT was prolonged. PT was 43.4 s and
PT-INR was 3.58 (normal range, 0.8–1.2). He did not
suffer from liver disease, and laboratory data for liver
function were normal. Given his high PT-INR with nor-
mal aPTT, FVII deficiency was suspected. A following
laboratory test of coagulation factors showed that only
FVII activity was significantly decreased to 1.4 % of nor-
mal. Since he was not taking any drugs that inhibit FVII
activity and had no FVII inhibitor, he was diagnosed
with congenital FVII deficiency.
We planned anesthetic management by general
anesthesia without epidural anesthesia for his surgery to
avoid bleeding associated with an epidural block proced-
ure. Fresh frozen plasma (FFP) or rFVIIa was not trans-
fused preoperatively. In the operating room, an
electrocardiogram, noninvasive blood pressure, percutan-
eous oxygen saturation, and nasopharyngeal temperature
were monitored. Radial artery pressure was also monitored.
General anesthesia was induced with propofol (3.0 μg ml−1
via target-controlled infusion (TCI)) and remifentanil
(0.3 μg kg−1 min−1), and then, the trachea was intubated
following administration of rocuronium. Anesthesia was
maintained with propofol (2.0–3.0 μg ml−1 via TCI),
remifentanil (0.1–0.3 μg kg−1 min−1), rocuronium
(5.0–7.0 μg kg−1 min−1), and oxygen-in-air gas mixture.
During the perioperative period, FVII activity and PT-
INR were monitored. PT-INR and FVII activity during
the clinical course are summarized in Table 1. Since
FVII activity and PT-INR were 1.5 % of normal and 3.66,
respectively, before starting surgery, 1 mg of rFVIIa
(15 μg kg−1), which is recommended by the manufac-
turer for patients with congenital FVII deficiency, was
intravenously administered immediately prior to surgery.
Then, surgery was started. It has been suggested that
FVII activity of less than 10 % is associated with
bleeding complications [5], and since the half-life of
rFVII is 2–4 h, we checked FVII activity during sur-
gery every 2 h to maintain FVII activity above 10 %.
Two hours after administration of rFVIIa, FVII activ-
ity was 205.7 % of normal, and PT-INR was normal-
ized to 0.9. The surgery was uneventfully completed
in 3 h and 46 min. Since FVII activity and PT-INR
were 86.8 % and 0.89, respectively, after completion
of surgery (4 h after administration of rFVIIa),
additional rFVIIa or FFP was not transfused. Blood
loss was 15 ml, and bleeding/oozing was not ob-
served. Since hemoglobin at the end of the surgery
was 12.1 g/dL, blood was also not transfused. After
the surgery, fentanyl-based intravenous patient-
controlled analgesia (iv-PCA) was started for postop-
erative pain management. The iv-PCA regimen was as
follows: a solution of 1400 μg fentanyl and 2.5 mg
droperidol mixed with physiological saline to a total
volume of 100 ml, 1 ml of bolus dose, 2 ml h−1 of
basal infusion, and 15 min of a lockout time. The
patient was transferred to the general ward in a stable
condition without any sign of hemorrhage.
The amount of drainage from the pelvic tube was
50 ml on postoperative day (POD) 1, but it increased to
125 ml and became bloody on POD 2. Therefore, 1 mg
of rFVIIa was administered intravenously on POD 2.
However, FVII activity and PT-INR were 1.7 % of nor-
mal and 2.93, respectively, and the fluid from the pelvic
tube was still bloody on POD 3. Therefore, rFVIIa was
repeatedly administered every 8 h until POD 4. Since
the amount of drainage from the pelvic tube was de-
creased to 55 ml and the drainage had become serous
fluid on POD 4, the pelvic drainage tube was removed
on POD 4. His postoperative pain was controlled well by
iv-PCA, and the pain intensity score at rest was 0–2 of
10 in numeric rating scale through the postoperative
period. The patient was discharged without any episode
of bleeding or thrombosis on POD 10.
Discussion
Although congenital deficiency of FVII increases the risk
of posttraumatic and postoperative bleeding [2], it is dif-
ficult to predict the perioperative risk of bleeding due to
a poor correlation between FVII activity and severity of
bleeding in patients with congenital FVII deficiency [6].
A recent retrospective study has suggested that FVII
activity of less than 10 % is a risk factor for bleeding
complications associated with a surgical procedure [5].
In our case, since preoperative FVII activity and PT-INR
were 1.4 % and 3.58, respectively, we planned to substi-
tute FVII.
Prothrombin complex concentrates, FFP, and rFVIIa
have been used to increase plasma FVII level. Admin-
istration of rFVIIa has become the most widely ac-
cepted therapeutic option for congenital FVII
Table 1 PT-INR and FVII activity during perioperative period
Preoperative
examination
During anesthesia POD 1 POD 3 POD 4
Before rFVIIa 2 h after rFVIIa 4 h after rFVIIa
PT-INR 3.58 3.66 0.9 0.89 2.18 2.93 1.46
FVII activity (%) 1.4 1.5 205.7 86.8 NA 1.7 NA
PT-INR prothrombin time-international normalized ratio, FVII factor VII, POD postoperative day, rFVIIa recombinant activated FVII, NA not assessed
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deficiency in surgical settings because no human
serum or proteins are used in the production of
rFVIIa [7]. National guidelines regarding the use of
blood products in Japan recommend administration of
each coagulation factor concentrate rather than FFP if
it is available. There are several reports showing the
effectiveness of administration of rFVIIa for peri-
operative coagulation management of a patient with
congenital FVII deficiency [3, 8].
While the optimal regimen for perioperative adminis-
tration of rFVIIa has still not been established, the rec-
ommended dose range of rFVIIa for general surgery is
15–30 μg kg−1 every 4–6 h until hemostasis is achieved
[9]. At least 10 % of FVII activity would be needed for
hemostasis [5]. In our case, the decision to administer
rFVIIa was made on the basis of assessment of FVII ac-
tivity and PT-INR. Accordingly, bolus administration of
15 μg kg−1 of rFVIIa was sufficient to maintain FVII ac-
tivity above 10 %, and additional administration of
rFVIIa was not needed during surgery. Since the time
course of FVII activity after rFVIIa administration is dif-
ferent in each patient [2], the measurement of FVII ac-
tivity would be useful for the determination of the dose
and timing of rFVIIa administration for each patient.
Possible complications of replacement therapy with
rFVIIa are thrombosis and production of antibodies
against FVII [9, 10]. A previous systematic review
showed that rFVIIa dose-dependently increased the risk
of arterial thromboembolic events in patients who
received a placebo or rFVIIa at doses of less than
80 μg kg−1, 80 to 120 μg kg−1, or more than 120 μg kg−1
[11]. Since the dose we administered (15 μg kg−1), which
is recommended for congenital FVII deficiency, is
lower than the doses used in that study, the risk for
thromboembolic events in our case might have been
relatively low. However, since surgical stress is a well-
known risk factor for thrombosis, administration of
rFVIIa during surgery may increase the incidence of
thromboembolic events. The measurement of the
FVII activity and PT-INR may be helpful for prevent-
ing overdose administration. Recently, continuous in-
fusion of rFVIIa has been used to maintain the
appropriate plasma concentration of FVII during sur-
gery [12]. It has been shown that continuous infusion
is safe, effective, well-tolerated, and cost-effective
compared to bolus administration. However, bolus
administration rather than continuous infusion is
recommended in Japan.
Conclusions
We reported successful management of a patient with
congenital FVII deficiency undergoing laparoscopic
colectomy with monitoring of FVII activity and/or
PT-INR.
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